547 results on '"Poch, Michael"'
Search Results
2. From Detection to Cure – Emerging Roles for Urinary Tumor DNA (utDNA) in Bladder Cancer
3. A Single Institution Experience in the Management of Localized Neuroendocrine Carcinoma of the Bladder
4. The Role of the Microbiome and Green Tea Catechins in Prostate Cancer: Contemporary Issues in Research
5. Gold standard nephroureterectomy, chemoprophylaxis and surveillance in upper tract urothelial carcinoma.
6. Prostatic Artery Embolization Is Safe and Effective for Medically Recalcitrant Radiation-Induced Prostatitis
7. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non–muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin
8. MP71-13 DELAYS IN INITIATING FIRST LINE BLADDER SPARING THERAPY PORTEND WORSE PROGRESSION-FREE SURVIVAL FOR BCG UNRESPONSIVE PATIENTS
9. Positive Ki-67 and PD-L1 expression in post-neoadjuvant chemotherapy muscle-invasive bladder cancer is associated with shorter overall survival: a retrospective study
10. NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016.
11. Effectiveness of perioperative chemotherapy and radical cystectomy in treating bladder cancer
12. Impact of surgical margin and extent of lymphadenectomy on oncologic outcomes in plasmacytoid urothelial carcinoma
13. Current State of Cell Therapies for Genitourinary Malignancies
14. Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis
15. Epidural anesthesia may be associated with increased postoperative complications in the elderly population undergoing radical cystectomy: an analysis from the National Surgical Quality Improvement Project (NSQIP) database
16. DISEASE PROGRESSION IN BCG UNRESPONSIVE PATIENTS: STRATIFICATION OF CIS CONTAINING TUMORS
17. IDENTIFYING THE DRIVER HISTOLOGY RESPONSIBLE FOR THE INFERIOR CLINICOPATHOLOGIC FEATURES ASSOCIATED WITH PLASMACYTOID BLADDER CANCER
18. PREOPERATIVE RADICAL CYSTECTOMY ERAS SCREENING AND EDUCATION – PATIENT REPORTED OUTCOMES
19. HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER WITH VARIANT HISTOLOGY OR OTHER SUBTYPES NOT A PREDICTOR FOR PROGRESSION IN BCG-TREATED PATIENTS
20. Abstract A020: An early determination of patients eligibility for a bladder cancer immunotherapy using a data science approach
21. Oncolytic Virotherapy Combined with Nivolumab Elicits Complete Responses in Muscle-Invasive Bladder Cancer in Association with the Formation of Tertiary Lymphoid Structures
22. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin–Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.
23. Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer
24. Survival Outcomes Associated With Female Primary Urethral Carcinoma: Review of a Single Institutional Experience
25. Clinical indications for necessary and discretionary hospital readmissions after radical cystectomy
26. 345 Targeting acidity in bladder cancer to enhance efficacy of adoptive cell therapy (ACT) with tumor reactive T cells
27. Targeting myeloid-derived suppressor cells with gemcitabine to enhance efficacy of adoptive cell therapy in bladder cancer
28. Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder
29. Data from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder
30. Table S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder
31. Management of Renal Masses in an Octogenarian Cohort: Is There a Right Approach?
32. Delay to Inguinal Lymph Node Dissection Greater than 3 Months Predicts Poorer Recurrence-Free Survival for Patients with Penile Cancer
33. Neoadjuvant Chemotherapy in Elderly Patients With Bladder Cancer: Oncologic Outcomes From a Single Institution Experience
34. Does Implementing an Enhanced Recovery After Surgery Protocol Increase Hospital Charges? Comparisons From a Radical Cystectomy Program at a Specialty Cancer Center
35. Perioperative Transfusion of Leukocyte-depleted Blood Products in Contemporary Radical Cystectomy Cohort Does Not Adversely Impact Short-term Survival
36. Green Tea Extract for Prevention of Prostate Cancer Progression in Patients on Active Surveillance
37. Sociodemographic and Provider Based Disparities in the Management of Stage I Testicular Cancer
38. Improved Outcomes of Enhanced Recovery After Surgery (ERAS) Protocol for Radical Cystectomy with Addition of a Multidisciplinary Care Process in a US Comprehensive Cancer Care Center
39. A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder
40. Preoperative Nutritional Status and Enhanced Recovery after Surgery (ERAS) Prior to Radical Cystectomy: A Review of the Literature
41. Management of Urethral Recurrences: Urothelial and Nonurothelial
42. Change in Management Based on Pathologic Second Opinion Among Bladder Cancer Patients Presenting to a Comprehensive Cancer Center: Implications for Clinical Practice
43. Predictors of Postoperative Complications in Patients Who Undergo Radical Nephrectomy and IVC Thrombectomy: A Large Contemporary Tertiary Center Analysis
44. Clinical Outcomes After Neoadjuvant Chemotherapy and Radical Cystectomy in the Presence of Urothelial Carcinoma of the Bladder With Squamous or Glandular Differentiation
45. Preoperative Patient Reported Mental Health is Associated with High Grade Complications after Radical Cystectomy
46. NEXT: A phase 2 study of nivolumab adjuvant to chemoradiation in patients (pts) with localized urothelial carcinoma.
47. Abstract CT157: Combination of nivolumab with standard of care in the management of grade group 5 prostate cancer: Interim analysis of a phase II trial
48. PD44-09 IMPACT OF HIGH-RISK FEATURES AND STAGING ON NEOADJUVANT CHEMOTHERAPY AMONG PATIENTS TREATED WITH RADICAL CYSTECTOMY: A SINGLE CENTER ANALYSIS OF 1700 CASES
49. PD09-09 SURVIVAL BENEFITS OF ADJUVANT CHEMOTHERAPY FOR POSITIVE SOFT TISSUE SURGICAL MARGINS FOLLOWING RADICAL CYSTECTOMY IN BLADDER CANCER WITH EXTRAVESICAL EXTENSION
50. Prostate cancer trends in Barbados: An analysis of the Barbados Urologic Diseases Survey database
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.